LLY

1,045.57

+3.75%↑

JNJ

230.89

+0.15%↑

ABBV

214.62

+0.91%↑

UNH

383.23

+0.51%↑

AZN

190.15

+1.08%↑

LLY

1,045.57

+3.75%↑

JNJ

230.89

+0.15%↑

ABBV

214.62

+0.91%↑

UNH

383.23

+0.51%↑

AZN

190.15

+1.08%↑

LLY

1,045.57

+3.75%↑

JNJ

230.89

+0.15%↑

ABBV

214.62

+0.91%↑

UNH

383.23

+0.51%↑

AZN

190.15

+1.08%↑

LLY

1,045.57

+3.75%↑

JNJ

230.89

+0.15%↑

ABBV

214.62

+0.91%↑

UNH

383.23

+0.51%↑

AZN

190.15

+1.08%↑

LLY

1,045.57

+3.75%↑

JNJ

230.89

+0.15%↑

ABBV

214.62

+0.91%↑

UNH

383.23

+0.51%↑

AZN

190.15

+1.08%↑

Home・Akciju saraksts・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Atvērts

29.31 -0.61

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

27.88

Max

29.73

Galvenie mērījumi
By Trading Economics
Ienākumi	43M 13M
Pārdošana	29M 107M
EPS	0.25
Peļņas marža	12.139
Darbinieki	524
EBITDA	16M 8.2M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+115.45% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 6. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-6.7M 1.4B
Iepriekšējā atvēršanas cena	29.92
Iepriekšējā slēgšanas cena	29.31

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

27.895 / 30.16 Atbalsts un pretestība

Immunocore Holdings PLC ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 20. maijs 23:31 UTC

Karstas akcijas

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

2026. g. 20. maijs 22:52 UTC

Galvenie tirgus virzītāji

Osisko Shares Fall on Planned Convertible Notes Offering

2026. g. 20. maijs 23:47 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 20. maijs 23:47 UTC

Tirgus saruna

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

2026. g. 20. maijs 23:44 UTC

Peļņas

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

2026. g. 20. maijs 23:35 UTC

Tirgus saruna

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

2026. g. 20. maijs 23:30 UTC

Tirgus saruna

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

2026. g. 20. maijs 23:17 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 20. maijs 23:17 UTC

Tirgus saruna

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

2026. g. 20. maijs 23:15 UTC

Tirgus saruna

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

2026. g. 20. maijs 23:14 UTC

Peļņas

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

2026. g. 20. maijs 23:02 UTC

Tirgus saruna

KMD Brands Faces Two Testing Hurdles -- Market Talk

2026. g. 20. maijs 22:57 UTC

Tirgus saruna

Infratil's Other Assets Deserve Attention, Too -- Market Talk

2026. g. 20. maijs 22:57 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 20. maijs 22:57 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 20. maijs 22:51 UTC

Tirgus saruna

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

2026. g. 20. maijs 22:51 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 20. maijs 22:27 UTC

Tirgus saruna

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

2026. g. 20. maijs 22:14 UTC

Tirgus saruna

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

2026. g. 20. maijs 22:10 UTC

Peļņas

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

2026. g. 20. maijs 22:00 UTC

Peļņas

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

2026. g. 20. maijs 21:38 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

2026. g. 20. maijs 21:27 UTC

Peļņas

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

2026. g. 20. maijs 21:20 UTC

Peļņas

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

2026. g. 20. maijs 21:19 UTC

Peļņas

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

2026. g. 20. maijs 21:18 UTC

Peļņas

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

2026. g. 20. maijs 21:17 UTC

Peļņas

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

2026. g. 20. maijs 21:17 UTC

Peļņas

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

2026. g. 20. maijs 21:17 UTC

Peļņas

Nvidia's Vera CPU Opens New $200B Market, CFO Says

2026. g. 20. maijs 21:16 UTC

Peļņas

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Immunocore Holdings PLC ADR Prognoze

Cenas mērķis

By TipRanks

115.45% augšup

Prognoze 12 mēnešiem

Vidējais 62.33 USD 115.45%

Augstākais 100 USD

Zemākais 33 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Immunocore Holdings PLC ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

10 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 10 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Immunocore Holdings PLC ADR — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

27.895 / 30.16Atbalsts un pretestība

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.